The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Post-marketing pharmacovigilance study of gilteritinib and midostaurin from the FAERS database
|
|
| Key learnings |
| A total of 46 safety signals were identified for midostaurin and 53 for gilteritinib. |
| The common AEs of both drugs were in line with findings from clinical trials. Midostaurin was most frequently associated with nausea, vomiting, diarrhea, pyrexia, and febrile neutropenia, while gilteritinib was associated with febrile neutropenia, pyrexia, anemia, and thrombocytopenia. |
| Both drugs produced unexpected AEs not listed on the label. Midostaurin exhibited 24 signals, including neutropenic colitis, neutropenic sepsis, septic shock, and hepatotoxicity. Gilteritinib exhibited 29 signals, including septic shock, neutropenic sepsis, cerebral hemorrhage, subdural hematoma, tumor lysis syndrome, and interstitial lung disease. |
| Limitations of the spontaneous report database, including reporting bias, lack of causal relationship between the drug and the AE, inability to calculate incidence and severity of AEs, and other confounding factors, highlight the need for further studies to validate the findings. |
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; FAERS, Food and Drug Administration Adverse Event Reporting System; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
